Michelle Mitchell, Chief Executive of Cancer Research UK (CRUK), shared a post on LinkedIn:
“Last week’s decision from NHS England is an important moment for men with high‑risk prostate cancer. Thousands more will now be offered abiraterone – a treatment rooted in research we helped make possible.
This progress is the result of decades of work by scientists we’ve funded, from discovering and developing abiraterone in the 1990s to generating the evidence through the STAMPEDE trial that showed how effective it can be for men with localised, high‑risk disease.
It’s a clear example of how sustained investment in research leads to meaningful impact. Each breakthrough builds on the last, creating progress that reaches people when they need it most.
Thank you to the researchers, clinicians and partners who made this possible. Together, we keep moving forward.
Michelle Mitchell OBE Recognized Among The 100 Most Influential People in Oncology in 2025
Michelle Mitchell